StockCIK 1534120
Avalo Therapeutics, Inc. (AVTX): Insider Trades and Fund Holdings
In the past 12 months, Avalo Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 6 sales worth $1.87M; 6 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$1.87MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 18, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 18 | Christopher Ryan SullivanCFO | ▼ SELL10b5-1 | $202K |
| Sep 11 | Christopher Ryan SullivanCFO | ▼ SELL10b5-1 | $179K |
| Sep 1 | Mittie DoyleChief Medical Officer | ▼ SELL10b5-1 | $14K |
| Aug 19 | Christopher Ryan SullivanCFO | ▼ SELL10b5-1 | $828K |
| Aug 19 | Christopher Ryan SullivanCFO | ▼ SELL10b5-1 | $622K |
| Aug 19 | Mittie DoyleChief Medical Officer | ▼ SELL10b5-1 | $20K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Christopher Ryan Sullivan | CFO | 0 | $0 | 4 | $1.83M |
| Mittie Doyle | Chief Medical Officer | 0 | $0 | 2 | $34K |
Tracked funds that report AVTX
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 357,200 | $6.60M | ▲ +197.4% |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →